Roger Hajjar

Roger Hajjar

Director/Board Member at LONGEVEROPAR

Net worth: 48 369 $ as of 31/07/2026

61 year
Health Technology
Consumer Services
Commercial Services

Profile

Dr. Roger J.
Hajjar
, MD, is an Independent Director at Longeveron, Inc., a Director-Gene & Cell Therapy at Mass General Brigham, Inc., a President, Director & Chief Medical Officer at Medera, Inc., a Chief Executive Officer at Sardocor Corp., a Head-Research & Development at Ring Therapeutics, Inc. and a President, Chief Medical Officer & Director at Medera, Inc. /New/.
He is on the Board of Directors at Longeveron, Inc., Atamyo Therapeutics SAS, Medera, Inc. and Medera, Inc. /New/.
Dr. Hajjar was previously employed as a Director-Cardiovascular Research Center by Icahn School of Medicine at Mount Sinai and a Director-Cardiovascular Research by Celladon Corp.
He also served on the board at Cellectis SA. He received his undergraduate degree from The Johns Hopkins University and a doctorate degree from Harvard Medical School.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
19/08/2026 69,000 ( 0.23% ) 48 369 $ 31/07/2026

Roger Hajjar active positions

CompaniesPositionStart
LONGEVEROPAR Director/Board Member 02/07/2024
Director/Board Member 24/07/2023
Corporate Officer/Principal 01/12/2022
Founder 01/01/2014
Chief Executive Officer -
Chief Tech/Sci/R&D Officer -

Former positions of Roger Hajjar

CompaniesPositionEnd
Corporate Officer/Principal 01/01/2019
Founder -
CELLECTIS S.A. Director/Board Member -
See the detail of Roger Hajjar's experience

Training of Roger Hajjar

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

75

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Consumer Services

Health Technology

Commercial Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology